Podcasts about genes

Allergist Tina Sindher acknowledges that allergies may be affecting more people worldwide, influenced by a combination of factors such as environmental changes, modern lifestyles, urbanization, and evolving dietary habits. Prevention is playing catch-up, and promising new strategies include earlier food introduction than was popular only a few years ago. On the treatment front, hopes are rising for immunotherapies and a new prescription medicine, omalizumab, that addresses multiple allergens at once. While no single approach helps all, these strategies could allow millions worldwide to better manage their allergies, Sindher tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Sayantani (Tina) SindherConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Tina Sindher, a professor of medicine and allergy at Stanford University.(00:03:16) Inside the Immune ResponseWhy our immune systems trigger allergic reactions.(00:04:57) Genes vs. EnvironmentWhether genetics or environment drive allergy risks.(00:08:05) The Microbiome FactorThe role of the microbiome and early exposures in prevention.(00:09:17) A Global Allergy SurgeHow global allergy trends reveal rising health challenges.(00:11:56) Potent Food TriggersWhy some foods cause stronger and faster reactions.(00:13:49) Emerging RisksWhether Alpha-Gal signals new emerging allergy risks.(00:15:47) Multi-Food AllergiesHow multi-food allergies complicate diagnosis and treatment.(00:19:02) Preventing Allergies EarlyWhy early food introduction may help prevent allergies.(00:20:54) Skin's Role in AllergiesThe importance of infant skin health in allergy development.(00:23:39) Testing LimitationsThe limits of current testing methods to truly diagnose allergies.(00:25:13) Standard Testing ProcedureThe current methodologies deployed when testing for allergies.(00:27:28) New TherapiesHow new therapies like OIT and Xolair are reshaping treatment.(00:31:50) The Future of AllergiesThe potential of combined therapies to aid in allergy treatment.(00:34:33) Managing Seasonal AllergiesHow to manage seasonal allergies effectively at home.(00:37:08) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

Education, Science - Genome BC

Clara Ramas analiza los efectos que tiene el hecho de ver un genocidio en directo y actualizado constantemente. La analista de Hora 25 reflexiona sobre las consecuencias sociales y políticas de la tecnología, algo que estamos viendo claramente en Gaza.

Una nueva forma para viajar, a traves de las grandes obras musicales del genero clasico. Conducido por Juan Fernando Villafuerte Ex colaborador de la Deutsche Welle de Alemania y la Elizabeth Trabanino, Directora de Radio Clasica, quienes a traves de una tertulia contaran las historias que se esconden detras de las operas a manera de poner en contexto al publico sobre el origen de estas grandes composiciones.

El núcleo de WordPress incorporará la funcionalidad nativa para tener imágenes integradas en los correos sin depender de enlaces externos o contenido en BASE64.

Our strategy gurus never shy away from controversy. In this episode, Mark and Lorraine dive into 2025's biggest advertising controversy – the Sydney Sweeney American Eagle Jeans/Genes campaign! See how the positioning duo impartially shares their thoughts on the campaign and why the stock soared, the jeans flew off the shelf, and how American Eagle may once again be relevant to a new generation.Join Mark and Lorraine for 30-ish as they discuss all things marketing, advertising, and of course … positioning!

EXETER UFO FESTIVAL: INHERTING A FATHER'S UFO BLUEPRINT? Nat Sticco- discussing her and her husband Genes work into Soviet era reverse engineering programs of UFOs. A Blueprint. Cold War era. The fall of the USSR. A Fathers Duty to Protect State secrets. #ufo #Disclosure #TotalDisclosureBecome a supporter of this podcast: https://www.spreaker.com/podcast/total-disclosure-ufos-coverups-conspiracy--5975113/support.Featuring Steven Bassett of PRG www.paradigmresearchgroup.org Featuring Nat and Gene Sticco www.Engineeringinfinitybook.com

Abrimos nueva temporada como a nosotros nos gusta...entrando en otro jardín. En esta ocasión trataremos de centrarnos en una famosa, rica y muy polémica familia. Esperamos que os guste. La música ha sido creada, registrada y cedida por Sir Edward Madrid. Podéis seguirnos en nuestras redes sociales o en los comentarios de IVOOX. Un cordial saludo

La civilización nipona esta hecha de leyendas ....

Este mes la azotea sonora de Talk to Him rinde homenaje a una de las bandas fundamentales de las últimas décadas: Nine Inch Nails. De la mano de Him, viajaremos a los orígenes de esta mítica formación construida en torno al genio Trent Reznor. De esta manera, recorreremos sus curiosos inicios coqueteando con el synthpop más al uso, pasaremos por la grabación de sus primeras demos recogidas en esa joya rareza entre fans que es Purest Feeling, nos detendremos en su gran disco debut, Pretty Hate Machine y todas las curiosidades que lo rodearon, sin dejar pasar por supuesto la tormentosa relación con algunos de sus componentes, en especial con Richard Patrick, deteniéndonos en analizar proyectos interesantísimos de sus colaboradores por entonces, desde Filter hasta el inquietante proyecto personal de Chris Vrenna, Tweaker. Imposible no hablar de todo el halo de violencia y sexualidad incluidos en la mismísima esencia de la banda desde siempre hasta llegar a su máxima expresión de furia y sadomasoquismo explícito plasmados en la concepción de su obra maestra en forma de EP, Broken, con algunos highlights como la grabación de un vídeo en en rancho donde Charles Manson pergeñó la matanza de Sharon Tate y compañía y asistiendo a la primera presentación en sociedad de un Brian Warner en los albores de convertirse en Marilyn Manson. Todo ello hasta llegar al cliffhanger más terrible de la historia del podcast, lo que se vendría encima con la descomunal etapa Downward Spiral.

Abrimos nueva temporada como a nosotros nos gusta...entrando en otro jardín. En esta ocasión trataremos de centrarnos en una famosa, rica y muy polémica familia. Esperamos que os guste. La música ha sido creada, registrada y cedida por Sir Edward Madrid. Podéis seguirnos en nuestras redes sociales o en los comentarios de IVOOX. Un cordial saludo Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Embryogenesis Genes⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Embryology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

U.S. housing regulator Bill Pulte began the campaign to remove Federal Reserve Governor Lisa Cook from her post. He explains his allegations against Lisa Cook and her colleagues at the central bank. Hundreds of employees at GE Aerospace facilities in Ohio are entering their eighth day on strike. Their representative, United Auto Workers President Shawn Fain, discusses the deal he rejected, the demands on the table, and the future of American auto manufacturing. Plus, American Eagle reported positive results from its controversial ad campaign with Sydney Sweeney, the NYC mayoral race is back in the headlines, President Trump is attempting to save his tariffs in the courts, and the White House has invited tech CEOs to the building's brand new patio.  Shawn Fain  19:42William J. Pulte 35:09 Shawn Fain, @ShawnFainUAWWilliam J. Pulte, @pulteEamon Javers, @eamonjaversBecky Quick, @BeckyQuickJoe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkinKlaire Odumody, @klairemarie

441-M-286-Id - 1635 - Las imágenes de galaxias tempranas tomadas por el telescopio Webb están proporcionando nuevos conocimientos sobre el universo primitivo. Y después, los faros de Aída. Universo de Misterios tiene reservado el derecho de admisión y publicación de comentarios. Generalmente, los comentarios anónimos no serán publicados. Si hace comentarios con afirmaciones dudosas, arguméntelas aportando enlaces a fuentes fiables (este muro NO es una red social). En caso de no respaldar su comentario como se indica en la caja de descripción del episodio, su comentario podrá ser no publicado. Contacto con Universo de Misterios: universodemisteriospodcast@gmail.com La imagen de la miniatura que ilustra este episodio ha sido creada con la ayuda de una Inteligencia Artificial. Puedes hacerte Fan de Universo de Misterios y apoyarlo económicamente obteniendo acceso a todos los episodios cerrados, sin publicidad, desde 1,99 €. Aunque a algunas personas, a veces, puede proporcionar una falsa sensación de alivio, la ignorancia nunca es deseable. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Nate is on vacation this week, so Maria is joined by journalist David Epstein, author of The Sports Gene and Range. They talk about a new company that offers comprehensive genetic sequencing on embryos during the IVF process—at a high price. What are the ethics of this kind of technology? And what are the risks (and rewards) of trying to optimize your child’s genes? Plus, they discuss a topic they’ve been texting about for years: Does your name determine who you become? Further Reading: You can find more about David and his writing on his website, https://davidepstein.com/. For more from Nate and Maria, subscribe to their newsletters: The Leap from Maria Konnikova Silver Bulletin from Nate SilverSee omnystudio.com/listener for privacy information.

Si sentís que las fotos de tus productos o los gráficos para redes no le hacen justicia a tu negocio, tenés que conocer la revolución de la IA generativa. En este episodio del miércoles 3 de septiembre de 2025, el 1843, hablamos de "Nano Banana" de Google. Te doy el plan para usarla estratégicamente.

Jerry Gore has always lived life on the edge; he had tackled some of the highest, and most inhospitable mountain climbs in the world before he was diagnosed with Type 1 diabetes aged 40.  His Type 1 diabetes has not held him back and he has learnt how to live well with his Type 1 diabetes when climbing at extreme altitude and bitter cold.  He helps people living with Type 1 diabetes throughout the world, especially in S E Asia as co-founder of Action4Diabetes (A4D). Rob Andrews is a national expert helping people with Type 1 diabetes to adapt their diabetes care so they can do any extreme activity including mountaineering, long distance swimming, and endurance cycling.Send us a text

En entrevista para MVS Noticias con Luis Cárdenas, Pontón, experto en tecnología, habló sobre Nano Banana: La IA gratis de Google para crear imágenes.See omnystudio.com/listener for privacy information.

Carreteras bloqueadas por deslizamientos de tierra y montañas colapsadas complican el acceso a las aldeas. Columnas de vehículos avanzan lentamente cargados de ayuda humanitaria, mientras helicópteros evacúan a los heridos hacia hospitales.See omnystudio.com/listener for privacy information.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Únete a nosotros en Patronus Unplugged, tu podcast en español especializado en Harry Potter, Animales Fantásticos y todo lo relacionado con el Wizarding World de la mano de Beatriz M. Arranz, Saida Herrero y Fernando Vidal. Volvemos tras unas pequeñas vacaciones con un nuevo programa exclusivo en el que comentamos las imágenes que se han filtrado del rodaje de la nueva serie de Harry Potter para HBO Max. Únete a nuestra comunidad en el siguiente enlace: https://discord.gg/aS3UMmj8nh Cualquier comentario será bienvenido por aquí, por nuestras redes sociales (o a través del hashtag #PatronusUnplugged) y a través de nuestro correo electrónico. https://www.instagram.com/patronusunplugged/ @PatronusUnplug PatronusUnplugged@gmail.comEscucha este episodio completo y accede a todo el contenido exclusivo de Patronus Unplugged. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/638268

Nous sommes en 1432. Alors qu'il voyage vers Bâle, l'humaniste Enea Silvio Piccolomini, futur pape Pie II, rédige une lettre dans laquelle il rapporte ses impressions sur la cité de Gênes, en Ligurie, au N-O de la péninsule italienne. Il écrit : « Le port est protégé par une jetée qui aurait coûté à peine plus si elle avait été construite en argent : la mer est d'une telle profondeur ici ! C'est un refuge sûr pour les bateaux qui viennent toujours mouiller en grand nombre. Ils viennent et repartent rapidement (…), certains de l'Est et d'autres de l'Ouest, de telle sorte que chaque jour l'on peut observer des hommes de différentes races, d'étranges et de rudes coutumes, mais aussi des marchands qui arrivent porteurs de toutes sortes de richesses. Bien plus, dans le quartier du port qui le raccorde à la ville, il y a de superbes palais en marbre qui touchent le ciel, extrêmement élégants et pourvus de nombreuses colonnes, dont beaucoup sont ornés de sculptures et de statues. À leur pied court un portique d'environ mille pieds de long où l'on peut acheter n'importe quelle sorte de marchandise. Le reste de la cité s'étend vers les collines : les grandes et belles maisons y sont si élégantes et somptueusement décorées qu'aucune d'entre elles ne disconviendrait à un roi ou à un prince : en effet, toutes ont une majesté régalienne, extrêmement grandes, et proches les unes des autres. », conclut le pas encore souverain pontife (il lui faudra attendre une vingtaine d'années). Quoiqu'il en soit, son éloge ne doit pas nous faire oublier qu'au XVe siècle Gênes se déchire dans de nombreuses guerres civiles. Ce qui n'empêchera pas le siècle suivant d'être son âge d'or : elle devient une pièce maîtresse de la puissance des Habsbourg et souffle les prémices d'un capitalisme mondial. Avec nous : Fabien Levy, docteur en histoire médiévale. « Histoire de Gênes – Le souffle du capitalisme mondial » ; Passés/Composés Sujets traités : Gênes, prémices, capitalisme, mondial, Enea Silvio Piccolomini, Pie II, Merci pour votre écoute Un Jour dans l'Histoire, c'est également en direct tous les jours de la semaine de 13h15 à 14h30 sur www.rtbf.be/lapremiere Retrouvez tous les épisodes d'Un Jour dans l'Histoire sur notre plateforme Auvio.be :https://auvio.rtbf.be/emission/5936 Intéressés par l'histoire ? Vous pourriez également aimer nos autres podcasts : L'Histoire Continue: https://audmns.com/kSbpELwL'heure H : https://audmns.com/YagLLiKEt sa version à écouter en famille : La Mini Heure H https://audmns.com/YagLLiKAinsi que nos séries historiques :Chili, le Pays de mes Histoires : https://audmns.com/XHbnevhD-Day : https://audmns.com/JWRdPYIJoséphine Baker : https://audmns.com/wCfhoEwLa folle histoire de l'aviation : https://audmns.com/xAWjyWCLes Jeux Olympiques, l'étonnant miroir de notre Histoire : https://audmns.com/ZEIihzZMarguerite, la Voix d'une Résistante : https://audmns.com/zFDehnENapoléon, le crépuscule de l'Aigle : https://audmns.com/DcdnIUnUn Jour dans le Sport : https://audmns.com/xXlkHMHSous le sable des Pyramides : https://audmns.com/rXfVppvN'oubliez pas de vous y abonner pour ne rien manquer.Et si vous avez apprécié ce podcast, n'hésitez pas à nous donner des étoiles ou des commentaires, cela nous aide à le faire connaître plus largement. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Sydney Sweeney gets exposed for having great GENES??? The monday crew gets into the whole controversay or should I say conspiracy !

You may hear the protest chant, “what do we want? Land rights!” —but what does it really mean? Land is at the heart of Aboriginal and Torres Strait Islander identity, culture, and wellbeing. Known as “Country,” it includes land, waterways, skies, and all living things. In this episode of Australia Explained, we explore Indigenous land rights—what they involve, which land is covered, who can make claims, and the impact on First Nations communities. - Puede que escuches el lema de protesta: "¿Qué queremos? ¡Derechos sobre la tierra!" —pero, ¿qué significa realmente? La tierra está en el corazón de la identidad, cultura y bienestar de los aborígenes y de los isleños del Estrecho de Torres. Lo que ellos conocen como "país," incluye la tierra, las vías fluviales, el cielo y todos los seres vivos. En este episodio de Australia Explained, exploramos los derechos sobre la tierra indígena —qué abarcan, qué tierras están consideradas, quién puede hacer reclamaciones y el impacto de esto en las comunidades de las Primeras Naciones.

In this episode of Behind the Genes, we explore how Artificial Intelligence (AI) is being applied in genomics through cross-sector collaborations. Genomics England and InstaDeep are working together on AI and machine learning-related projects to accelerate cancer research and drive more personalised healthcare. Alongside these scientific advances, our guests also discuss the ethical, societal and policy challenges associated with the use of AI in genomics, including data privacy and genomic discrimination. Our guests ask what responsible deployment of AI in healthcare should look like and how the UK can lead by example. Our host, Francisco Azuaje, Director of Bioinformatics Genomics England is joined by Dr Rich Scott, Chief Executive Officer at Genomics England Karim Beguir - Chief Executive Officer at InstaDeep Harry Farmer – Senior Researcher at Ada Lovelace Institute If you enjoyed today's conversation, please like and share wherever you listen to your podcasts. And for more on AI in genomics, tune in to our earlier episode: Can Artificial Intelligence Accelerate the Impact of Genomics? "In terms of what AI's actually doing and what it's bringing, it's really just making possible things that we've been trying to do in genomics for some time, making these things easier and cheaper and in some cases viable. So really it's best to see it as an accelerant for genomic science; it doesn't present any brand-new ethical problems, instead what it's doing is taking some fairly old ethical challenges and making these things far more urgent."   You can download the transcript, or read it below.   Francisco: Welcome to Behind the Genes. [Music plays] Rich: The key is to deliver what we see at the heart of our mission which is bringing the potential of genomic healthcare to everyone.  We can only do that by working in partnership.  We bring our expertise and those unique capabilities.  It's about finding it in different ways, in different collaborations, that multiplier effect, and it's really exciting.  And I think the phase we're in at the moment in terms of the use of AI in genomics is we're still really early in that learning curve. [Music plays] Francisco: My name is Francisco Azuaje, and I am Director of Bioinformatics at Genomics England.  On today's episode I am joined by Karim Beguir, CEO of InstaDeep, a pioneering AI company, Harry Farmer, Senior Researcher at the Ada Lovelace Institute, and Rich Scott, CEO of Genomics England.  Today we will explore how Genomics England is collaborating with InstaDeep to harness the power of AI in genomic research.  We will also dive into the critical role of ethical considerations in the development and application of AI technologies for healthcare.  If you've enjoyed today's episode, please like, share on wherever you listen to your podcasts. [Music plays] Let's meet our guests. Karim: Hi Francisco, it's a pleasure to be here.  I am the Co-Founder and CEO of InstaDeep and the AI arm of BioNTech Group, and I'm also an AI Researcher. Harry: I'm Harry Farmer, I'm a Senior Researcher at the Ada Lovelace Institute, which is a think-tank that works on the ethical and the societal implications of AI, data and other emerging digital technologies, and it's a pleasure to be here. Rich: Hi, it's great to be here with such a great panel.  I'm Rich Scott, I'm the CEO of Genomics England. Francisco: Thank you all for joining us.  I am excited to explore this intersection of AI and genomics with all of you.  To our listeners, if you wish to hear more about AI in genomics, listen to our previous podcast episode, ‘Can Artificial Intelligence Accelerate the Impact of Genomics', which is linked in this podcast description. Let's set the stage with what is happening right now, Rich, there have been lots of exciting advances in AI and biomedical research but in genomics it's far more than just hype, can you walk us through some examples of how AI is actually impacting genomic healthcare research? Rich: Yeah, so, as you say, Francisco, it is a lot more than hype and it's really exciting.  I'd also say that we're just at the beginning of a real wave of change that's coming.  So while AI is already happening today and driving our thinking, really we're at the beginning of a process.  So when you think about how genomics could impact healthcare and people's health in general, what we're thinking about is genomics potentially playing a routine part in up to half of all healthcare encounters, we think, based on the sorts of differences it could make in different parts of our lives and our health journey.  There are so many different areas where AI, we expect, will help us on that journey.  So thinking about, for example, how we speed up the interpretation of genetic information through to its use and the simple presentation of how to use that in life, in routine healthcare, through to discovery of new biomarkers or classification that might help us identify the best treatment for people.  Where it's making a difference already today is actually all of those different points.  So, for example, there's some really exciting work we're doing jointly with Karim and team looking at how we might use classification of the DNA sequence of tumours to help identify what type of tumour - a tumour that we don't know where it's come from, so what we call a ‘cancer of unknown primary' - to help in that classification process.  We're also working with various different people who are interested in classification for treatment and trials, but there's also lots in between recognising patterns of genomic data together with other complex data.  So we've been doing a lot of work bringing image data together with genomic data and other health data so that you can begin to recognise patterns that we couldn't even dream of.  Doing that hand in hand with thinking about what patients and participants want and expect, how their data is used and how their information is held, bringing it all together and understanding how this works, the evidence that we need before we can decide that a particular approach is one that policymakers, people in healthcare want to use, is all part of the conversation. Francisco: Thank you, Rich, for speaking of cutting-edge AI applications and InstaDeep.  Karim, could you give us a glimpse into your work and particularly how your technologies are tackling some of the biggest challenges in genomic research? Karim: Absolutely, and I think what's exciting is we've heard from Rich and, you know, this is like the genomics expertise angle of things and I come from the AI world and so do most of the InstaDeep team.  And really what's fascinating is this intersection that is being extremely productive at the moment where technologies that have been developed for like multiple AI applications turn out to be extremely useful in understanding genomic sequences.  This is a little bit, our journey, Francisco.  Back in 2021/2022 we started working on the very intriguing question at the time of could we actually understand better genomic sequences with the emerging technologies of NLP, natural language processing.  And you have to put this in context, this was before even the word ‘generative AI' was coined, this was before ChatGPT, but we had sort of like an intuition that there was a lot of value in deploying this technology.  And so my team, sort of like a team of passionate experts in research and engineering of AI, we tackled this problem and started working on it and the result of this work was our nucleotide transformer model which we have open sourced today; it's one of the most downloaded, most popular models in genomics.  And what's interesting is we observed that simply using the technologies of what we call ‘self-supervised learning' or ‘unsupervised learning' could actually help us unlock a lot of patterns. As we know, most of genomics information is poorly understood and this is a way actually, with using the AI tool, to get some sense of the structure that's there. So how do we do this?  We basically mask a few aspects of the sequence and we ask the system to figure them out.  And so this is exactly how you teach a system to learn English, you know, you are teaching it to understand the language of genomics, and, incredibly, this approach when done at scale - and we train a lot on the NVIDIA Cambridge-1 supercomputer – allows you to have results and performances that are matching multiple specialised models.  So until then genomics and use of machine learning for genomics was for a particular task, I would have developed a specific model using mostly supervised learning, which is, I am showing you a few examples, and then channelled these examples and tried to match that, and so essentially you had one model per task.  What's really revolutionary in this new paradigm of AI is that you have a single model trained at very largescale, the AI starts to understand the patterns, and this means that very concretely we can work with our partners to uncover fascinating relationships that were previously poorly understood.  And so there is a wealth of potential that we are exploring together and it's a very exciting time. Francisco: What you're describing really highlights both the potential and the opportunities but also the responsibility we have with these powerful tools, its power, and this brings up some important ethical considerations.  And we have Harry…  Harry, we have talked about ethics frameworks in research for decades but AI seems to be rewriting the rulebook.  For your work at the Ada Lovelace Institute what makes AI fundamentally different from previous technologies when it comes to ethical considerations and how does this reshape our approach to ensuring these powerful tools benefit society as a whole? Harry: So I think when you are considering these sorts of ethical questions and these sorts of ethical challenges posed by AI and genomics it really depends on the sort of deployment that you're looking at.  From the conversation we've had so far, I think what's been hinted at is some of the diversity of applications that you might be using AI for within the context of genomics and healthcare.  So I think there's obviously big advances that have been alluded to in things like drug discovery, in things like cancer and cancer diagnosis, also these advances around gene editing, all of which have been on steroids, by artificial intelligence and particularly machine learning and deep learning. The area that we have been looking at at the Ada Lovelace Institute, and this was a project that we were doing in collaboration with the NCOB, the Nuffield Council on Bioethics, was looking at what we were calling ‘AI-powered genomic health prediction', which is very related to a technique called ‘polygenic scoring', for those who might be interested.  And that's looking at the emerging ability to make predictions about people's future health on the basis of their DNA, and it was thinking about what that ability might mean for UK society and also for how we are thinking about and delivering healthcare in the UK. Now, thinking about what the ethical challenges might be for that, I think you need to think about what specifically AI is bringing to that technique, so what it's bringing to genomic health prediction.  I think with some of the other deployments, the list of things that AI is bringing is quite similar, so it's helping with data collection and processing, so speeding up and automating data collection and preparation processes that otherwise are quite slow and very labour-intensive.  AI's also helping with the analysis of genomic and phenotype data, so helping us to understand the associations between different genomic variations and between observable traits, and this is something which without AI can often be prohibitively complex to do, and it's also sometimes suggested that on the deployment end AI can be a tool that can help us use genomic insight in healthcare more widely.  So one example of this might be using an AI chat bot to explain to a patient the results of a genomic test.  That's something that's only been mooted and I don't think there are current examples of that at the moment but that's one of the downstream applications of AI in the context of genomics. So in terms of what AI's actually doing and what it's bringing, it's really just making possible things that we've been trying to do in genomics for some time, making these things easier and cheaper and in some cases viable.  So really it's best to see it as an accelerant for genomic science; it doesn't present any brand-new ethical problems, instead what it's doing is taking some fairly old ethical challenges and making these things far more urgent.  So in terms of what those problems actually are, some of the big ones will be around privacy and surveillance, genomic health predictions produce a lot of intimate sensitive data about people and generating those insights requires the collection and the storage and the processing of a lot of very sensitive data as well.  We also have issues related to privacy around genomic discrimination, so this is the worry that people will be treated differently and in some cases unfairly on the basis of health predictions made about them.  And one of the really typical examples here is the worry that people might face higher insurance costs if they're found through genomic testing to be more likely to develop particular diseases over their life course. And then you also have a bunch of issues and questions which are more structural, so these are questions about how the availability of this kind of insight into people's future health might change or put pressure on existing ways of thinking about health and thinking about healthcare and some extreme cases thinking about the social contract.  So these are questions like does the viability of genomic health prediction lead to a radically more preventative approach to healthcare and what might this mean for what the state demands of you as a user of healthcare and as a recipient of that.  And there are also some important questions about the practicalities of delivering genomic medicine in the NHS, so questions like how does the NHS retain control and sovereignty over genomic analysis and data capacities, how do we test their efficacy at a public health level, and also – and this is something that we might talk about a bit later – what's the best deployment model for these capacities.  So that's some of the ethical and I think policy challenges that we need to be dealing with in this space. Francisco: Thank you, Harry.  And those principles you have outlined provide a solid foundation for discussing different types of applications. [Music plays] Let's talk about the InstaDeep and Genomics England partnership that is investigating the application of InstaDeep's powerful foundation model, the nucleotide transformer, and other cutting edge techniques to address several challenges in cancer research.  I have the privilege of working closely with this partnership and the potential here is immense.  Karim, could you break down for our listeners what you are working on together and what innovations you are aiming for? Karim: Absolutely, Francisco.  Actually, we are very excited by the collaboration with Genomics England.  Genomics England not only has one of the best data assets in the world when it comes to genomics, like a very well curated dataset but also a wealth of expertise on these topics, and on my side the InstaDeep team brings fundamental knowhow of machine learning models but also, as you mentioned, like powerful developed models already, such as our nucleotide transformer and others.  The culture of InstaDeep has always been to build AI that benefits everyone – this is literally in our mission – and so in particular, specifically on like current topics, really like the goal is to try to identify partners between genomic sequences of patients and the particular phenotypes or approaches.  And one of the key projects, which I mentioned that, is the one of cancer of unknown primary origin.  So when you have situations where you are not sure where a particular cancer emerged from it is critical to be able to extract this information to have the best potential care, and this is actually something where understanding of genomic sequences can bring this capability.  And so we've been getting some successful results in the collaboration but in many ways this is just the beginning.  What we are seeing is a great wealth of possibilities linking genotypes, so the information which is on the sequences themselves, the genomic sequences, and phenotypes, like the particular state of the patient, and the fact that the Genomics England team has those joint datasets creates incredible opportunities.  So we are looking at this really like identifying together what are the most useful ‘low-hanging fruits', if you want, in terms of like potentially improving a patient's care and moving forward from that. Francisco: And this collaborative approach you are describing raises questions about accelerating innovation in general.  When two organisations like Genomics England and InstaDeep come together it's like a multiplier effect in terms of expertise, data, and other resources.  Could you both share how this partnership is accelerating discoveries that might have taken years? Rich: Yeah, I mean, I think this…  Francisco, you frame it really nicely because this is what makes it so exciting to be in our position at Genomics England because what we do is we bring the particular understanding and expertise, digital infrastructure and custodianship of the National Genomic Research Library together, but actually the key is bringing the potential of genomic healthcare to everyone.  We can only do that by working in partnership, we bring our expertise and those capabilities.  And, as you say, it's about finding it in different ways, in different collaborations, that multiplier effect, and it's really exciting.  And I think the phase we're in at the moment in terms of the use of AI in genomics is we're still really early in that learning curve.  And so, as you've heard already through what Karim and I have said and also what Harry has said, there are multiple different aspects that we need to look at together, bringing different angles and understandings, and we see ourselves…  We often describe ourselves as a ‘data and evidence engine', that final word ‘evidence' is really important and it comes in the round.  So Harry really eloquently talked about a number of different considerations from an ethical perspective that need to be there.  What we need if we're going to move genomics forwards in terms of its potential to make a difference for people's lives, we need evidence around clinical efficacy of different approaches, that's absolutely a given and everyone always jumps at…  so it's almost first in line.  We need understanding about the health economics, you know, how much difference does it make for a particular investment, is it worth that investment.  Critically, it also is founded on, you know, how you might use this technology in different ways, how you use it in clinical pathways, you know, is it something that actually is addressing the particular questions which really hold back the delivery of better care.  Also in that evidence piece is an understanding of patients' and participants' expectations on how their data might be used, their expectations on privacy, the expectations that we have on understanding how equitable the use of a particular approach might be, or at least our understanding of how confident we are about the equity of the impact, and it's bringing together those different perspectives.  And that's one of the things that helps us construct the team at Genomics England so we have the expertise to help others access the data in the National Genomic Research Library for purposes our participants support but also help generate that sort of rounded package of evidence that will end up moving the dial.  So that it's not just about proving a cool widget, because that's great on its own, what drives Karim and the team is to make a difference in terms of outcomes, and that's exactly what drives us and our participants too. Francisco: And this and other partnership approaches brings up important questions about responsible innovation, and this naturally leads us to the next question for Harry, how do we harness these powerful tools when protecting our communities? Harry: Yeah, so if we are thinking about over-surveillance and the ways that vulnerable groups might be affected by the use of genomics and healthcare, I think we're talking about at least two different things here.  So one problems around the representativeness of data is it does lead to issues which you could classify as issues of differential accuracy.  So in the context of genomic prediction what you have is genomic predictive tools being more accurate for white Europeans and those with white European ancestry compared to other population groups.  And this is a product of the fact that genomic datasets and genomic predictions, the terminologies don't port well between different populations, which means if you train a genomic predictive tool on a bunch of people with white European ancestry the predictions you might make using that tool for other groups won't be as accurate as for the white Europeans.  And this can be actively harmful and dangerous for those in underrepresented groups because you are making predictions about people which just won't have the accuracy that you would expect in the context that you were deploying it. And I already mentioned this a bit in my previous answer, you have worries about discrimination, and there are a few different things here.  So with some historically marginalised groups and marginalised groups now there are longstanding historical sensitivities about being experimented on, about particular fears about eugenics and about being categorised in particular ways.  And it's worth saying here that there is obviously a racial dimension to this worry but I think there's also a class dimension, by which I mean you're far more vulnerable to being categorised unfavourably if you're poor or if you don't have a particular kind of status within society.  There is also within discrimination the idea that genomics might be used to explain away differences between different groups which in fact have a political or an economic basis.  So one example of this was during the COVID-19 pandemic, there were attempts by some commentators to explain away the fact that non-white communities had worse rates of mortality from COVID to try and attribute a genetic or a genomic basis to those differences rather than looking at some of the socioeconomic factors behind that.  So those are some worries as well. Now, when it comes to protecting particular groups I think there are a few things that can be done fairly straightforwardly.  So, one is work to improve the diversity and the representativeness of datasets.  Obviously, that's easier said than done, though it's a very clear thing that we can aspire towards and there is good work, I'm aware, that is going on in this space, some of which is being spearheaded by Genomics England, amongst other groups.  Another is just being very careful about how the results of population level genomic studies are communicated to avoid giving that impression of explaining away differences between different groups simply as things determined by genomics about which we can do nothing rather than things which have historical or socioeconomic bases.  But I also think the broader lesson is that some of these harms and these forms of discrimination are things that could theoretically affect anyone; they're not just limited to affecting marginalised groups. Genomic health predicting can produce bases for all of us to be discriminated against, things that have nothing to do with our race, our class, our sex or any other protected characteristic.  So I think there has to be thinking about how we establish or sure up more universal protections against genomic discrimination.  One thing that we can do here is simply stronger data protection law, and one of the things that we talk about in some of our reports is that how data protection law as it stands could do with being less ambiguous when it comes to how it treats genomic data and phenotype data produced as a result of genomic analysis. [Music plays] Francisco: Harry, you are in a unique position at the Ada Lovelace Institute where you bridge this gap between AI developers, researchers, policymakers and the public.  Your recent report on AI in genomics with the Nuffield Council on Bioethics offers an important blueprint for responsible AI innovation in general, so based on this cross-sector perspective, what guiding principles do we need to embrace as we navigate this intersection of AI and genomics? Harry: So I think in addition to the specific recommendations we set out in the final report of that work - which is called ‘Predicting the Future of Health' and which you can find on our website and also on the NCOB website – I think one of the biggest messages was the importance of finding a deployment model for genomic health prediction that respects that technology's strengths, what it can actually do, because there are limitations to this technology, and also which avoids circumstances in which the associated risks are difficult to deal with.  So another way of putting this is that we need a deployment model that, as well as making sure that we're ready to cope with the risks of genomic health prediction, the things like law, regulation and governance also proactively tries to design out some of those risks and finds ways of deploying this technology such that those risks don't present themselves in either as extreme a manner or don't present themselves in ways which makes them difficult to deal with. So one question that we posed in our research was whether some ways of integrating genomic health prediction may present more challenges regarding privacy, discrimination and then these other challenges that we'd identified around dependency and fragility and others. And having looked at some of the different broad approaches to using genomic health prediction within the NHS and within the UK's health system, we found that one presented by far fewest of the risks identified above, while still presenting some of the most certain benefits of genomic health prediction.  And this was using it really primarily as a targeted diagnostic tool - and this is a vision in which the NHS uses genomic health prediction quite sparingly in the first instance - and in situations to improve treatment and outcomes for those who are seriously ill or who have been identified as needing to take particular precautions regarding their health.  We think the more situational vision has a few advantages.  So one, is it allows patient and people using the health service to retain greater control over data.  We think that can also have a positive knock-on effect for worries about discrimination.  And here what you have is the absence of those pressures to share your data.  It means that it's easier for you as the user of the healthcare system to resist genomic discrimination simply by keeping your data private.  And there are some cases where that option… it shouldn't be the only option but where that option is really important. And then also one of the features of this vision is that the smaller scale of the use of genomic health prediction, presumed, can make outsourcing to third parties, which the NHS is probably likely to need to do in some cases.  It's also a vision, I think, that overall allows you to capture some of the more certain benefits to genomic health prediction which are about improvements to accuracy in predictions about people's future health at the margin, and therefore this is a deployment of this technology which is deploying it principally to people who will benefit and we know will benefit from marginal improvements in accuracy to predictions made about their future health rather than wanting to deploy those marginal improvements to the vast majority of the population where the benefit is less certain.  So this is a vision we hope sets out a way of getting some of the more certain benefits of this technology while minimising some of those broader more systemic risks. Francisco: Thank you, Harry.  Karim? Karim: Totally agree with Harry about the need for smart regulation in the field so that we make sure we have good uses of the technology but avoid the potential pitfalls.  I wanted to emphasise two points which I believe are important.  First, we are really in a fast-moving situation when we look at like AI progress.  We have seen incredible improvements over the last ten years and in particular what we call ‘artificial general intelligence', which is essentially systems that are matching human cognitive abilities, are now around the corner.  This might sound surprising but literally the last obstacles to reach AGI are being solved right now, and this means that in the next 12-24 months you will have systems that are incredibly capable.  So this emphasises the need for the type of measures and type of smart approach that Harry has described.  And I would say when you look at the intersection of AI and genomics this is a particularly important one and why it's the case, because so far in genomics our obstacle has not been data, it has been interpretation of a flood of data.  The progress that AI is making, like I just described now, means that very soon extraordinary capabilities will be available to improve patients' outcomes.  I want to inject a sense of how important is our conversation today, given what is happening, an exponential progress in AI, exponentially growing data in genomics and relatively exponential potential to build the technology for good.  But, like in other fields, we see that AI is an extremely powerful technology and we need to make sure it is used for good in fact and this is why the conversation that we have today is so important. Harry: Obviously I agree with the conclusion to all of this, is that we need to think very hard about the way that artificial intelligence and its deployment in healthcare and also just in many different walks of life is going to be affecting the way we think about public service delivery, affecting the way that we think about scientific development.  It's worth noting, though, that I think one of the biggest challenges from a policy perspective on artificial intelligence is being able to distinguish the wheat from the chaff.  There are obviously areas where AI has made huge and incredibly impressive progress over the past few years and where we reasonably expect that to continue over the next few years, but there are also areas where some of the stories being told about the capabilities of future systems probably won't be matched by the reality, but there is I think a really big and very live debate about exactly what we can reasonably expect from these technologies and therefore what the deployments of them are. Francisco: Thank you.  We are approaching the end of the episode and I'd like to conclude with a couple of questions.  Genomics England has built quite an ecosystem of industry partnerships, how do collaborations like the one with InstaDeep fit into your broader mission for the company? Rich: So linking this to the conversation that we've just been having, which is AI is making a real difference in terms of technologies that we can test, we can develop evidence on, and that is rightly creating excitement, I think our approach…  The expectation of our participants is that our role is to sit there and help people develop evidence and you can make judgments on policy based on those and that is what will drive adoption.  I think the thing that really excites me for the UK, most particularly in genomics, is our ability to be the place in the world where you can come with a new technology, whether it's genomic sequencing technology, whether it's a genomic AI approach to train that to develop evidence on its efficacy, and, if it's proven to be effective to be worth the bang for the buck to perform to the expectations that patients, the public, would have of it in terms of equity and so forth also to deploy it.  I think there is a real reason for excitement around that and it's a real opportunity that the government has highlighted and that we absolutely buy into that the UK can be the best place to do that for academics and for industry.  And our participants see real opportunity and are eager for that work to be done so that we have the evidence on which to decide what should be deployed and where.  We see opportunities in all sorts of different areas, so certainly in terms of drug discovery and all the way through to simplifying tasks which at the moment just limit the rate at which the existing uses of genomics in healthcare can happen. So I think there's opportunities across the whole length, if you like, the sort of end to end, and the breadth of opportunity, and industry, companies like InstaDeep and others that we work with, are really crucial to that.  And what we do is think about the digital infrastructure we need to, you know, have those teams able to interact with within the National Genomic Research Library carrying out their approved research projects.  Also what support they need, and that comes in different shapes and sizes, depending on the ask and also the company.  So sometimes sort of leaning in more, particularly at the start of programmes, to help people shape the question, working with our participants, thinking about the wider evidence that you might need, for example, those sort of things that Harry's touched on, but also thinking about what hands-on support companies need, because not every company is anywhere close to Karim and InstaDeep's expertise.  Sometimes this is also about supporting people to have some of those tools that they don't have or some of the knowhow that's very specific to areas of genomics, so it's absolutely crucial to it.  And I think that point of the UK being the place to come and develop that evidence in its full breadth so that policy decisions can be made not based on hype but on evidence in the round, on what will make a difference. Francisco: And, Karim, looking ahead, also in retrospect, what have been your key learnings about making this cross-sector partnership work? Karim: We live in an extraordinary time and I want to emphasise the potential of scientific discovery in the next two or three years.  AI is going to move from, let's say, digital style, you know, technologies like coding and maths towards more like science and biology.  In particular, genomics is going to be a fascinating area in terms of potential, and I agree with Rich and Harry, it's all in the end about proving on the ground the potential of those capabilities.  And at InstaDeep we are passionate about the tech – I think you might have felt that – but we're also passionate about the applications.  The best results come when you bring expertise from multiple domains; machine learning and AI experts will require the expertise of genomic experts, biologists, healthcare practitioners, to be able to translate the potential of those technologies in concrete outcomes.  And we've seen this on multiple successful projects we've done with Genomics England but really this suggests that we are going to have in the next 3-5 years way more progress than we had in the last five and really my wish is that collectively we seize this opportunity and we do it in a responsible and thoughtful manner. [Music plays] Francisco: We'll wrap up there.  Thank you to our guests, Karim Beguir, Harry Farmer and Rich Scott, for joining me today as we discuss the role of AI in genomics research.  If you wish to hear more like this, please subscribe to Behind the Genes on your favourite podcast app.  Thank you for listening.  I have been your host, Francisco Azuaje.  This podcast was edited by Bill Griffin at Ventoux Digital and produced by Naimah Callachand. [Music plays]    

The nation is on the doorstep of Canaan. In our Parsha, the people are instructed in how they must treat the Canaanite inhabitants of the land. It's not pleasant. The people are told that they must engage in total war against these nations. How do we understand the requirement to be so violent and aggressive […]

The nation is on the doorstep of Canaan. In our Parsha, the people are instructed in how they must treat the Canaanite inhabitants of the land. It's not pleasant. The people are told that they must engage in total war against these nations. How do we understand the requirement to be so violent and aggressive towards the Canaanite nations? What about the Canaanites who opt to join the nation? What is their status? In this podcast, we first explore the general notion of how to understand the Torah's instructions regarding the Canaanite policy, and then we explore a very interesting thread about the power of behavior and how it can get embedded in the spiritual DNA that we transmit to our descendants.– – – – – – – – – – – – – – – – – – – – – –DONATE: Please consider supporting the podcasts by making a donation to help fund our Jewish outreach and educational efforts at https://www.torchweb.org/support.php. Thank you!– – – – – – – – – – – – – – – – – – – – – –Email me with questions, comments, and feedback: rabbiwolbe@gmail.com– – – – – – – – – – – – – – – – – – – – – –SUBSCRIBE to my Newsletterrabbiwolbe.com/newsletter– – – – – – – – – – – – – – – – – – – – – –SUBSCRIBE to Rabbi Yaakov Wolbe's PodcastsThe Parsha PodcastThe Jewish History PodcastThe Mitzvah Podcast This Jewish LifeThe Ethics PodcastTORAH 101 ★ Support this podcast ★

Hubo primero un ataque contra el hospital Nasser en Gaza. Empezaron a llegar los servicios de rescate. Los periodistas, para contarlo. Por eso esta vez hay vídeo. Estaban tomando imágenes. Se ve -se les ve a lo lejos- a personas con chalecos naranjas. Con guantes. Se ve cómo se organizan para tratar de sacar a los heridos. Fue un ataque contra los periodistas. Ayer el ejército israelí mató a cinco. A cinco en un hospital. Luego, mataron a otro de un disparo en Al Mawasi. Netanyahu ha dicho que valora el trabajo de los periodistas y que el bombardeo al hospital fue un accidente. De momento han matado a más de 240 periodistas según las autoridades gazatíes. Se llamaban Hossam Al Masri, Mohamed Salama, Mariam Abu Daqqa, Moaz Abu y Ahmed Abu Aziz. 

Every mystery leaves a trail of clues. Fingerprints, call logs, maybe some tire tracks… or, of course, DNA. And when it comes to mysteries about our health, there are no shortages of leads to chase.This season, join host, Dr. –or Detective– Kaylee Byers and the Nice Genes! CSI unit as we investigate the genomic breadcrumbs shaping the way we age, treat diseases– and even watch TV. We'll uncover how “poo water” can tip us off to pandemics before they spread, to why some of the fittest athletes suddenly collapse on the field. And if you thought you smelled a “rat,” well, you'd be correct. Because we'll also learn how our rodent sidekicks are helping us sniff out the world's deadliest infectious disease.Explore these cases and more in Nice Genes! season 5: “DNA Detectives”– resolving the genetic riddles behind our health, one story at a time.

Tras casi una década de lucha, en 1975, el entonces primer ministro australiano Gough Whitlam le otorgó al pueblo gurindji el arrendamiento de una parcela de tierra en la estación ganadera de Wave Hill, en el Territorio del Norte.

Listen to Jay Garvens Home & Mortgage Show at 8am.  This show he talks about how Denver is taking Colorado’s genes away from them! On KRDO New Radio 105.5FM & 1240AM Saturdays and 11am on... The post WHY IS DENVER DESTROYING OUR GENES – 08-16-25 appeared first on Jay Garvens.

Listen to Jay Garvens Home & Mortgage Show at 8am.  This show he talks about how Denver is taking Colorado's genes away from them! On KRDO New Radio 105.5FM & 1240AM Saturdays and 11am on... The post WHY IS DENVER DESTROYING OUR GENES – 08-16-25 appeared first on Jay Garvens.

Join Physique University (free for 2 weeks) to engineer your best physique using our science-based fat loss and muscle-building blueprint—Why can two people follow the same diet and training plan but get completely different results? Could your DNA explain why fat loss feels harder, or why recovery takes longer? And is genetic testing the breakthrough it claims to be or just another fitness gimmick?With me is Joe Cohen, founder and CEO of SelfDecode, to separate the science from the scams. Joe shares what your genes can actually tell you about building muscle, losing fat, and preventing disease, and where the industry is misleading you. We also dig into how combining genetic data with lab work creates actionable steps you can measure and adjust over time.Tune in to discover whether your DNA could be the missing piece in your fitness journey.Today, you'll learn all about:0:00 – Intro2:17 – Why most DNA health tests fail6:44 – Marketing hype vs real science9:59 – Moving beyond the fitness basics12:01 – Diseases genetics can predict well16:38 – Universal habits vs targeted actions18:15 – How SelfDecode prioritizes recommendations22:43 – Genes and training insights27:22 – Pathways and functional genetics31:17 – Combining genetics with lab work38:07 – Joe's story of food intolerance45:45 – Where to learn more about SelfDecodeEpisode resources:Website: SelfDecode.comInstagram: @mrbiohacker Facebook: @selfdecode X: @SelfDecode Support the show

This week, we talk about the American Eagle ad that has caused a lot of backlash. We also talk about a zoo in Denmark with an unusual request. And we talk about how some churches have made authenticity an "idol". Watch this episode now or listen on any podcast platform! Sydney Sweeney Fronts Ad Campaign for Jeans—Sparks Debate About Eugenicshttps://www.newsweek.com/sydney-sweeney-american-eagle-ad-controversy-2105004Denmark zoo asks people to donate unwanted pets to feed predators and imitate ‘natural food chain'https://www.cnn.com/2025/08/04/europe/denmark-aalborg-zoo-pets-predators-intl-hnkHave We Made ‘Authenticity' an Idol?https://relevantmagazine.com/faith/have-we-made-authenticity-idol/

Welcome true believers to X-Men Horoscopes where each week our host Lodro Rinzler is in conversation with a special guest to discuss the X-Men issue that aligns with a significant month and year from their life and what that issue reveals about their future. With us today are the co-hosts of The X-Wife Podcast, Alicia and Justin Wilder. We dive into their wedding anniversary issue - a heist issue known as X-Men Red 6 - as well as how they got together, and even see how they rate as a couple with our brand-new segment: the X-Newlywed Games! Also in this episode: the new revamp of the X-Wife Podcast - it's bi now! Everything is Magik a deep dive on everyone's favorite X-Man: Gentle Abslantis Searebro How your brain waves can totally ride the ocean waves All this plus we spend way too long arguing about both Inferno and Wolverine. What does any of this mean for their future as a couple? Tune in to find out! Alicia Wilder is a multifaceted performer based in Rhode Island. She graduated from Rhode Island College with a BA in Dance and minors in Theatre & Film. Alicia is the founder and Artistic Director/Choreographer of Metamorphosis: the TEN31 Dance Company and works as a Living Art & Character performer with TEN31 Productions.  She has been performing and producing shows professionally for over 14 years. Alicia is also a lifelong nerd, avid cosplayer and is the Co-Host of The X-Wife Podcast. Her passion for costume making combined with her love for nerd culture has launched her headfirst into the world of conventions, cosplay and nerd events. Justin Wilder is a digital content creator and co-host of The X-Wife Podcast with his wife Alicia, an elaborate scheme to get her into X-Men comics disguised as a podcast. He's a full time videographer, photographer and drone pilot who teaches and performs improv comedy in spare time. Outside of work you'll find him playing disc golf, snowboarding, and exploring the great outdoors. More of Lodro Rinzler's work can be found here and here and you can follow the podcast on Instagram at xmenpanelsdaily where we post X-Men comic panels...daily. Have a question or comment for a future episode? Reach out at xmenhoroscopes.com

Most people think iron is only a concern if they're deficient, but too much iron can be just as dangerous. In this episode, I sit down with Dr. Christy Sutton, a leading figure in the study of iron imbalances, to explore the often-overlooked health epidemic of unrecognized iron overload. Anchored around her book, The Iron Curse, we discuss why outdated laboratory ranges often fail to detect these imbalances and why recognizing them is so crucial for long-term health. From there, we dive into the intricacies of iron metabolism and the need for updated functional health ranges tailored to healthy populations. Dr. Sutton explains how imbalances can signal underlying health problems and highlights the value of functional lab testing in catching issues conventional methods often miss. We also explore the role of genetic testing—especially for hereditary hemochromatosis—and how genetics and environmental factors work together to influence iron levels. Key Takeaways: Iron Imbalance Epidemic: Iron imbalances, particularly overload, are often underdiagnosed due to outdated lab ranges and misconceptions, representing a silent health epidemic. Functional vs. Conventional Ranges: Functional health ranges, as opposed to traditional lab ranges based on sick populations, are crucial for accurate diagnosis of iron-related health conditions. Importance of Genetic Testing: Genetic factors (hemochromatosis genes) play a significant role in iron overload, necessitating comprehensive testing beyond typical lab work. Dietary and Lifestyle Influences: Both high and low iron levels are influenced by diet, lifestyle, and, importantly, how iron interacts with other nutrients and lifestyle factors like exercise. Gender and Iron Requirements: Iron needs differ significantly by sex and life stages, with menstrual and post-menopausal women, as well as men, needing tailored iron management strategies. More About Dr. Christy Sutton, D.C.: Dr. Christy Sutton is interested in asking why health problems happen and finding the safest and least problematic solutions. Her work takes a deep and meaningful dive into genomics, labs testing and creating a personalized health plan. Her focus on finding and avoiding health landmines early stems from her personal experience with Crohn's and celiac disease plus her husband's experience with high iron, hemochromatosis, and a pituitary tumor that likely was associated with having undiagnosed hemochromatosis. Website Instagram Connect with me! Website Instagram Facebook YouTube This episode is sponsored by Professional Co-op®, where clinicians gain exceptional access to industry-leading lab services without the hefty price tag—since 2001, they've been redefining what efficient, patient-focused support looks like. Imagine no hidden fees, no minimums, and only paying for completed tests. Experience lab services that not only meet but also exceed your expectations. Join the co-op trusted by countless licensed clinicians nationwide. Visit www.professionalco-op.com to learn more! This episode is also made possible by Functional Medicine University. FMU is a fully online, self-paced training program in functional medicine, founded in 2006 by Dr. Ron Grisanti. With students in all 50 U.S. states and 68 countries globally, FMU has become a cornerstone in advanced clinical education for healthcare practitioners. The curriculum is led by Dr. Grisanti, alongside contributions from over 70 distinguished medical experts on FMU's advisory board. Graduates earn the prestigious Certified Functional Medicine Practitioner (CFMP®) credential upon completion. FMU is also a nationally approved provider of continuing education for a wide range of licensed professionals, including MDs, DCs, DOs, NDs, acupuncturists, PAs, NPs, nurses, dietitians, pharmacists, and dentists. Whether you're looking to expand your clinical knowledge or bring a functional approach to your practice, FMU offers the tools, guidance, and certification to help you thrive. Visit www.functionalmedicineuniversity.com to learn more!

Nels and Vincent discuss research on hidden evolutionary constraints that dictate the retention of coronavirus accessory gene, which was flagged by NIH as potentially dangerous gain-of-function research. Hosts: Nels Elde and Vincent Racaniello Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiEVO Links for this episode Join the MicrobeTV Discord server Hidden evolutionary constraints and retention of coronavirus accessory genes (Curr Biol) Timestamps by Jolene Science Picks Nels – NIH suspends dozens of pathogen studies over ‘gain-of-function' concerns and Mentorship and acts of kindness Vincent – Kennedy's case against mRNA vaccines collapses under his own evidence Music on TWiEVO is performed by Trampled by Turtles Send your evolution questions and comments to twievo@microbe.tv

Follow The Show:PatreonDiscordYoutubeInstagramX(Twitter)Follow Cipha Sounds:InstagramX(Twitter)TikTokFollow Rosenberg:InstagramX(Twitter)TIkTokThis podcast is sponsored by Monster Energy and Monster Music. Hosted on Acast. See acast.com/privacy for more information.

This week we talk all about the pop culture we've missed over the past couple of weeks!We have a Patreon! We have two bonus episodes per month: Celebrity Corner and Bad Book Club, released each month! If you want to hear more from us, support us ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!Join our Culture Gang! Email us at culturehangpodcast@gmail.com and follow us on instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@culturehangpodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

My guest is Dr. Sergiu Pașca, MD, professor of psychiatry and behavioral sciences at Stanford University. We discuss the biology and genetics of autism, why autism diagnoses are increasing and recent progress in using stem cells to understand and treat profound autism and other brain disorders. Dr. Pașca explains “organoids and assembloids”—human stem cell–derived tools he pioneered to study, treat and cure complex brain diseases. We also discuss ethical and safety issues with using gene editing and stem cells in humans. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman Helix: https://helixsleep.com/huberman BetterHelp: https://betterhelp.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00) Sergiu Pașca (02:08) Autism Spectrum Disorder, Incidence, Genetics (07:16) Is Autism More Common in Males? (09:35) Sponsors: David & Helix Sleep (11:56) Eye Contact in Babies, Fever; Proposed Causes of Autism; Genes (18:48) Genetic or Idiopathic Autism Diagnoses, Timothy Syndrome (21:37) Rise in Autism Diagnoses (26:46) Cause, Correlation & Neurological Disease; Schizophrenia, Do Vaccines Cause Autism? (31:34) Global Increase in Autism; Gene Therapy, CRISPR, Follistatin (41:05) Sponsors: AG1 & BetterHelp (43:41) Stem Cells, Ethics, Yamanaka Factors, Human Stem Cell Models (52:03) Umbilical Stem Cells; Stem Cell Injections & Dangers, Autistic Kids (59:30) Organoids, Modeling Brain Development, Intrinsic Development Timer (1:12:22) Assembloids, Brain Cell Migration & Circuit Formation, Self-Organization (1:21:22) Four-Part Assembloid, Sensory Assembloid, Pain Conditions (1:25:45) Sponsor: Function (1:27:33) Future Medical Therapies, Cell Banking, Immortalize Tissues, Rejuvenate Cells (1:34:56) Assembloids & Ethics, Importance of Nomenclature, Science Collaboration & Self-Correction (1:45:38) Cell Transplantation & Ethics, Timing (1:55:05) Genetic Testing for Parents, Genetic Penetrance (2:02:36) Assembloids, Timothy Syndrome, Epilepsy, Schizophrenia, Dystonia (2:14:30) Scientific Career, Walking, Art, Medical School (2:20:44) Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Allie Beth Stuckey joins Jason to discuss the viral controversy surrounding Sydney Sweeney's American Eagle ad and the reactions it received. They also explore why conservatives on social media are celebrating attractive women on the internet. Learn more about your ad choices. Visit megaphone.fm/adchoices

About this episode:  Sickle cell disease affects an estimated 100,000 people in the United States. Recent advancements in gene therapies and medicines like hydroxyurea are diminishing extreme pain, reducing strokes, and extending survival times for those afflicted by the disease. In this episode: leading sickle cell disease expert Dr. Mark Gladwin explains how revolutionary new treatments work and discusses the challenges to access to life-saving care. Guest: Dr. Mark Gladwin is a physician-scientist and the Dean of the University of Maryland School of Medicine and Vice President for Medical Affairs at the University of Maryland, Baltimore. His research focuses include sickle cell disease and hypertension. Host: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle—CNBC Gene Therapy: What You Need to Know—Sickle Cell Disease Association of American No More Pain: Breakthrough Sickle Cell Treatment from Johns Hopkins Offers Curative Potential—Johns Hopkins School of Medicine Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Dr. Jill sits down with Dr. Dennis G. Hooper, M.D., Ph.D. to decode the mysteries of autoimmunity and explore how environment and nutrition shape our genes. Dr. Hooper shares his remarkable journey from traditional medicine to integrative and functional medicine, offering insights into groundbreaking programs on inflammasomes and their critical role in autoimmune conditions. Together, Dr. Jill and Dr. Hooper dive deep into the effects of environmental exposures like arsenic and iron contamination, while highlighting the role of nutritional genetics in restoring health. You'll also discover the innovative Silver Gene Initiative, designed to transform patient care with faster lab testing and more accessible results. This conversation emphasizes the importance of teaching, collaboration, and community in medicine—and how collective knowledge can revolutionize healthcare for the future.

In this conversation, Michael Shermer and Dr. Eric Topol discuss the realties of aging, with particular focus on the role of AI in enhancing patient care and disease prevention, the importance of lifestyle factors, and the limitations of genetic testing in predicting health outcomes. Topol also explains the dangers of ultra-processed foods, their link to inflammation, and the role of GLP-1 drugs in promoting healthier eating habits. The conversation also covers diet, particularly the differences between chicken and red meat, and the significance of sleep for overall health. Plus, consumption of microplastics, cholesterol management and statins, the critical role of social connections in maintaining mental and physical health, and the future of personalized medicine in cancer prevention. Eric Topol is a cardiologist and one of the top ten most cited researchers in medicine, known for his groundbreaking studies on AI in medicine, genomics, and digitized clinical trials. Topol is also the executive vice president and a professor of molecular medicine at Scripps Research, the largest nonprofit biomedical institute in the United States. He was named one of the Top 100 most influential people in health in 2024 by Time. His new book is Super Agers.

Longtime cohost Mike D rejoins the show for a special 3 hour + investigation of the new Baskin Robbins new advertisement, Dunkin Donuts ingredient lists, and American school lunches vs those from oversees. As the MAHA movement seeks to change schools lunches, opponents argue that it is difficult, expensive and laborious, yet other countries with less money and resources have already perfected the school lunch. So what is going on in the U.S.?*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKWEBSITECashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

Topics:  In this bonus episode, Brant talks about what he's learning from the book: "The Matter With Things" by Iain McGilchrist. Including: - Exploring the complexity and intelligence of living cells. - Challenging purely mechanical views of biology. - Why relationships and context are paramount.   And most importantly…   The many spiritual parallels that can be derived from the book and how who we are becoming matters way more than our past.     Quotes: “Life requires cognition at all levels. Our cells think!” “Genes do nothing on their own; life is far more than DNA.” “Flatworms can regrow their brains and still remember.” “Healing is God's work; medicine cooperates with it.” . . . Holy Ghost Mama Pre-Order! Want more of the Oddcast? Check out our website! Watch our YouTube videos here. Connect with us on Facebook! For Christian banking you can trust, click here!

Demi in Martha's Vineyard (on Appleton Estate); Shannon Shape is more than just a dirty old man; Mad Black people just got re-married; And Just Like That (Finally) Cancelled; Mad Spoilers for The Gilded Age; Beyoncé joins the jeans/genes controversy. Learn more about your ad choices. Visit podcastchoices.com/adchoices

America's sweetheart - or the face of a quiet eugenics campaign? In this episode, we unpack the new Sydney Sweeney x American Eagle ad that's been praised by the right as a return to “traditional American values” — and why it has people whispering about the Great Replacement Theory. From Trump chiming in to say he “loves it” to online conservatives treating Sydney like the poster girl for “healthy, white motherhood,” we explore how fashion branding becomes soft propaganda, how the ad taps into white nationalist aesthetics, and why it's never just denim. Check out ⁠⁠⁠⁠⁠⁠https://www.squarespace.com/fluently⁠⁠⁠⁠⁠⁠ to save 10% off your first purchase of a website or domain using code FLUENTLY Elevate your closet with Quince. Go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Quince.com/fluently⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for free shipping on your order and 365 -day returns.

I recap my interview with Tucker Carlson, Trump withholds disaster funds for states unless they support Israel, and an unexpected group of people have come to my side and issued a public letter to Brigitte Macron. 00:00 - Start. 01:03 - My interview with Tucker. 04:29 - The Saint Laurent/Macron connection. 24:43 - Trump to withhold disaster funding for states and cities who boycott Israel. 33:10 - Hunter Biden's Channel 5 interview. 48:32 - Comments. GoldCo Get a FREE gold & silver kit! #goldcopartner http://www.candacelikesgold.com Just Thrive Get 20% off your order with promo code CANDACE at https://justthrivehealth.com PureTalk Make the switch today and get a FREE Samsung Galaxy A36 with a qualifying plan at http://www.PureTalk.com/Owens American Financing Call American Financing today to find out how customers are saving an avg of $800/mo. 800-795-1210 or visit http://www.AmericanFinancing.net/owens NMLS 182334, https://www.nmlsconsumeraccess.org Candace Official Website: https://candaceowens.com Candace Merch: https://shop.candaceowens.com Candace on Apple Podcasts: https://t.co/Pp5VZiLXbq Candace on Spotify: https://t.co/16pMuADXuT Candace on Rumble: https://rumble.com/c/RealCandaceO Learn more about your ad choices. Visit megaphone.fm/adchoices

After a week of controversy from an online AE ad that went all the way up to the White House, American Eagle finally issued a statement. BUT, as Amy and T.J. discuss, that statement pissed some people off even more than the original ad! The question, should we be mad, or should we be asking ourselves WHY we’re so mad and how can we all do better?See omnystudio.com/listener for privacy information.

My guest is Dr. Nirao Shah, MD, PhD, a professor of psychiatry, behavioral sciences and neurobiology at Stanford University School of Medicine. We discuss how the brains of males and females differ and how those differences arise from different genes and hormones during fetal development, in childhood and adulthood. We discuss what drives male- versus female-specific behaviors and how hormonal fluctuations across the lifespan, including puberty, the menstrual cycle, menopause and aging – affect behavior, cognition and health. Additionally, we discuss how biology relates to gender identity and the impact of hormone therapies on brain circuits that regulate mating, parenting and social bonding. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Maui Nui: https://mauinuivenison.com/huberman Eight Sleep: https://eightsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps 00:00:00 Nirao Shah 00:02:11 Mice, Humans & Brain, Biological Conservation 00:05:25 Hormones, Nature vs Nurture 00:07:13 Biological Sex Differences, Chromosomes & SRY Gene, Hormones 00:16:01 Sponsors: Maui Nui & Eight Sleep 00:19:09 Androgen Mutations, Feminization & Masculinization 00:22:04 SRY Gene; Animals & Sexual Trans-Differentiation 00:27:49 Hormones & Biological Brain Differentiation 00:31:22 Congenital Adrenal Hyperplasia, Androstenedione; Stress & Pregnancy 00:35:56 Genes, Brain Differentiation & Sexual Identity; Congenital Adrenal Hyperplasia 00:43:37 Testosterone, Estrogen & Brain Circuits 00:47:27 Sponsors: AG1 & LMNT 00:50:36 Intersex Individuals, Castration 00:52:23 Female Sexual Behavior, Brain, Testosterone & Pheromones 00:57:58 Identify as Heterosexual or Homosexual, Difference in Hormone Levels? 01:00:42 Gender, Sexual Orientation & Hormones; Hormone Replacement Therapy 01:10:21 Aromatization; Steroid Hormones & Gene Expression 01:15:00 Kids & Changing Gender Identity 01:19:05 Sexual Behavior, Refractory Period & Male Brain, Tacr1 Cells 01:21:31 Sponsor: Function 01:23:19 Hypothalamus, Dopamine, Prolactin, Cabergoline, Libido, Dopamine 01:27:05 Brain Circuits, Aggression & Sexual Behavior 01:32:40 Refractory Period; Age, Testosterone & Libido 01:36:07 Tacr1 Cells in Females, Periaqueductal Gray & Innate Behaviors 01:40:00 Parenting Behaviors & Brain Circuits; Pet Dogs 01:43:12 Oxytocin, Pair Bonding, Vasopressin; Biological Redundancy 01:47:22 Libido, Melanocortin, Tacr1 Neurons; GLP-1 Agonists, Clinical Trials; Kisspeptin 01:56:43 Female Brain Changes, Menstrual Cycle, Pregnancy, Menopause; Estrogen; Men & Hormone Fluctuation? 02:04:10 Life Experience Male vs Female, Sex Recognition, Behaviors & Context 02:16:05 Pain Management; Endocrine Disrupters, Gender Identity 02:21:03 Future Projects 02:24:29 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices